Mourabit Halima, Author at MediaMedic

Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China

By Mourabit Halima 2024.03.18

Introduction: Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a pivotal therapeutic modality for lymphoma and multiple myeloma (MM), offering promising outcomes in improving patient prognosis. In China, the…

The Prognostic Power of Tumor-Infiltrating B Cells in Diffuse Large B-cell Lymphoma: Implications for Precision Medicine

By Mourabit Halima 2024.03.18

Abstract: In the realm of diffuse large B-cell lymphoma (DLBCL) prognosis, the emergence of tumor-infiltrating B lymphocytes (TIL-Bs) as potent prognostic indicators has sparked a new wave of research and…

Anlotinib: A Promising Therapeutic Approach for Transformed Follicular Lymphoma

By Mourabit Halima 2024.03.18

Introduction: Transformed follicular lymphoma (tFL) presents a formidable challenge in clinical oncology due to its high tumor mutational burden and therapeutic resistance. While anlotinib has demonstrated efficacy in solid tumors,…

The Role of SHP-1 and SHP-2 in CD8+ T Cell Regulation during Lymphocytic Choriomeningitis Virus Infection: Insights into Stage-Specific Functional Interplay

By Mourabit Halima 2024.03.18

Abstract: Our study delves into the intricate interplay between Src homology region 2 domain-containing phosphatases 1 and 2 (SHP-1 and SHP-2) in orchestrating the functionality of CD8+ T cells during…

Assessing the Impact of Omicron Variant on Allo-HSCT Recipients in China: Insights from a Single-Center Observational Study

By Mourabit Halima 2024.03.17

Introduction: The emergence of the Omicron variant of SARS-CoV-2 has posed significant challenges to global public health systems. Among vulnerable populations, allo-hematopoietic stem cell transplantation (allo-HSCT) recipients represent a particularly…

Exploring CD22 as an Alternative Target in B-cell Hematologic Malignancies: A Comprehensive Review of Study Design, Clinical Implications, and Future Perspectives

By Mourabit Halima 2024.03.17

Abstract: Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has revolutionized the treatment landscape for patients with relapsed or refractory (R/R) B-cell malignancies. However, the emergence of relapse with CD19-negative…

$Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results$

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

By Mourabit Halima 2024.03.17

Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…

Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

By Mourabit Halima 2024.03.17

Abstract: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy associated with significant morbidity and mortality. Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown promise as a therapeutic agent…

Retrospective Analysis of bZIP Region Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia: Implications for Prognosis and Treatment

By Mourabit Halima 2024.03.17

Editor's note: Acute Myeloid Leukemia (AML) characterized by CCAAT-enhancer binding protein alpha (CEBPA) double mutations (CEBPAdm) represents a distinct subtype with varying clinical outcomes. Recent attention has focused on the…

The Impact of CEBPA Mutations in Hematological Disorders: A Comprehensive Study

By Mourabit Halima 2024.03.17

Editor's note: Genetic mutations play a pivotal role in shaping the clinical presentation and prognosis of hematological disorders, with CEBPA mutations emerging as significant contributors to disease pathogenesis. This comprehensive…